Cipla ties up with CSIR-CDRI

16 Feb 2024 Evaluate

Cipla has tied up with CSIR-Central Drug Research Institute (CDRI) to jointly develop a novel ophthalmic formulation for fungal keratitis. The collaboration aims to leverage the combined expertise and resources of both organisations to develop a safe and efficacious drug for fungal keratitis.

CSIR-CDRI has developed a prototype formulation for an anti-fungal drug to optimise its delivery in the eye. In pre-clinical studies, this formulation supports faster resolution of the infection. Cipla will scale up the product, conduct the required studies and seek regulatory approvals for commercialisation, ensuring accessibility for those in need, according to the statement.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. 


Cipla Share Price

1406.25 0.85 (0.06%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.